REGENXBIO Statistics
Share Statistics
REGENXBIO has 49.55M shares outstanding. The number of shares has increased by 1.13% in one year.
| Shares Outstanding | 49.55M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.25% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 44.68M |
| Failed to Deliver (FTD) Shares | 365 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 6.23M, so 12.57% of the outstanding shares have been sold short.
| Short Interest | 6.23M |
| Short % of Shares Out | 12.57% |
| Short % of Float | 13.89% |
| Short Ratio (days to cover) | 4.99 |
Valuation Ratios
The PE ratio is -2.98 and the forward PE ratio is -9.71.
| PE Ratio | -2.98 |
| Forward PE | -9.71 |
| PS Ratio | 8.7 |
| Forward PS | 1.7 |
| PB Ratio | 2.52 |
| P/FCF Ratio | -3.44 |
| PEG Ratio | n/a |
Enterprise Valuation
REGENXBIO Inc. has an Enterprise Value (EV) of 839.79M.
| EV / Earnings | -3.19 |
| EV / Sales | 9.31 |
| EV / EBITDA | -3.51 |
| EV / EBIT | -3.13 |
| EV / FCF | -3.68 |
Financial Position
The company has a current ratio of 2.57, with a Debt / Equity ratio of 0.
| Current Ratio | 2.57 |
| Quick Ratio | 2.57 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -39.07 |
Financial Efficiency
Return on equity (ROE) is -0.85% and return on capital (ROIC) is -66.82%.
| Return on Equity (ROE) | -0.85% |
| Return on Assets (ROA) | -0.46% |
| Return on Capital (ROIC) | -66.82% |
| Revenue Per Employee | 262.33K |
| Profits Per Employee | -765.97K |
| Employee Count | 344 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -152.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -53.96% in the last 52 weeks. The beta is 1.23, so REGENXBIO 's price volatility has been higher than the market average.
| Beta | 1.23 |
| 52-Week Price Change | -53.96% |
| 50-Day Moving Average | 8.95 |
| 200-Day Moving Average | 12.22 |
| Relative Strength Index (RSI) | 37.7 |
| Average Volume (20 Days) | 1.18M |
Income Statement
In the last 12 months, REGENXBIO had revenue of 90.24M and earned -263.49M in profits. Earnings per share was -6.02.
| Revenue | 90.24M |
| Gross Profit | 53.03M |
| Operating Income | -268.13M |
| Net Income | -263.49M |
| EBITDA | -239.46M |
| EBIT | -268.13M |
| Earnings Per Share (EPS) | -6.02 |
Balance Sheet
The company has 34.52M in cash and 89.29M in debt, giving a net cash position of -54.77M.
| Cash & Cash Equivalents | 34.52M |
| Total Debt | 89.29M |
| Net Cash | -54.77M |
| Retained Earnings | -705.05M |
| Total Assets | 519.11M |
| Working Capital | 210.67M |
Cash Flow
In the last 12 months, operating cash flow was -218.41M and capital expenditures -9.96M, giving a free cash flow of -228.37M.
| Operating Cash Flow | -218.41M |
| Capital Expenditures | -9.96M |
| Free Cash Flow | -228.37M |
| FCF Per Share | -5.22 |
Margins
Gross margin is 58.76%, with operating and profit margins of -297.12% and -291.99%.
| Gross Margin | 58.76% |
| Operating Margin | -297.12% |
| Pretax Margin | -292.15% |
| Profit Margin | -291.99% |
| EBITDA Margin | -265.36% |
| EBIT Margin | -297.12% |
| FCF Margin | -253.06% |
Dividends & Yields
RGNX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -85.63% |
| FCF Yield | -65.61% |
Analyst Forecast
The average price target for RGNX is $37, which is 426.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $37 |
| Price Target Difference | 426.3% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
Scores
| Altman Z-Score | -2.16 |
| Piotroski F-Score | 3 |